TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05300217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategies for promoting mental health
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health
Study: NCT04985292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic, Lactobacillus
Description: 10\^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance packaged to be identical to active treatment
Study: NCT04917003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIC plus EDAS
Description: Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.

Intervention type: OTHER
Group type: OTHER
Intervention: EDAS
Description: Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
Study: NCT05457855

Intervention type: DRUG
Intervention: Montelukast
Description: Montelukast claim is used as the exposure group.

Intervention type: DRUG
Intervention: Fluticasone
Description: Fluticasone claim is used as the reference group.
Study: NCT05136885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005
Description: Administration: Infusion Dose: 0.75 g/kg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
Study: NCT06219356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-002
Description: Administered orally according to the assigned treatment schedule.
Study: NCT05300217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General information about depression
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression
Study: NCT06045364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anisodamine
Description: During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
Study: NCT04878562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-COPE
Description: The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
Study: NCT06043674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glofitamab
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Antibody-drug conjugate, 30 mg or 140 mg vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Humanized immunoglobulin monoclonal antibody, 840 mg/14 mL or 1200 mg/20 mL single-use vial, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.
Study: NCT05163366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP A
Description: Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B
Description: The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
Study: NCT06578923

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.

Intervention type: BEHAVIORAL
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.

Intervention type: BEHAVIORAL
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
Study: NCT06180824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelafundin
Description: Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
Study: NCT06301529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Invokana Pill
Description: 100 mg and 150 mg doses, taken every day and every-other day, respectively.
Study: NCT06219356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-002
Description: Administered orally according to the assigned treatment schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-002
Description: Administered orally according to the assigned treatment schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-002
Description: Administered orally according to the assigned treatment schedule.
Study: NCT06059261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Description: Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
Study: NCT05917184

Intervention type: OTHER
Intervention: Telehealth
Description: Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
Study: NCT06242548

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic)
Description: organisation of 4 physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic).~During each of of the 4 physical activity outings, collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise).
Study: NCT06521697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture
Description: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture vs placebo normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture
Description: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture vs placebo normal saline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimal flow sevoflurane
Description: Minimal flow sevoflurane anesthesia (0.5 L/min) vs low flow sevoflurane (1 L/min)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimal flow sevoflurane
Description: Minimal flow sevoflurane anesthesia (0.5 L/min) vs low flow sevoflurane (1 L/min)
Study: NCT06301529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Invokana Pill
Description: 100 mg and 150 mg doses, taken every day and every-other day, respectively.
Study: NCT05269719

Intervention type: PROCEDURE
Intervention: Suture of digital nerve
Description: The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
Study: NCT05399082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoprobe biopsy
Description: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
Study: NCT04936100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of distance and near visual acuity using Vision Screening module of Easy Vision application
Description: The presenting visual acuity will be assessed using the Vision Screening module of the Easy Vision application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of distance and near visual acuity using Test Yourself module of Easy Vision application
Description: The presenting visual acuity will be assessed using the Test Yourself module of the Easy Vision application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of distance and near visual acuity using Peek Acuity application
Description: The presenting visual acuity will be assessed using the Peek Acuity application.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of distance and near visual acuity using the conventional methods
Description: The presenting visual acuity will be assessed using the conventional methods \[Chart: Tumbling E optotype for assessing distance visual acuity and Handheld chart: Tumbling E Near Point Vision Chart for assessing near visual acuity\]
Study: NCT05609760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIMAP
Description: Pictographic depiction of medical indications alongside standard communication of these recommendations.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
Study: NCT05808387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Trans-resveratrol, 1000 mg daily for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch, 1000 mg daily for 90 days
Study: NCT06537453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Care
Description: Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
Study: NCT06184984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolic availability of methionine in mung beans
Description: Each participant will randomly receive 7 different levels of methionine provided as free amino acids and cooked mung beans.
Study: NCT05426551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual isotope method
Description: The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual isotope method
Description: The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual isotope method
Description: The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
Study: NCT05662072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Mental imagery of respiratory exercises
Study: NCT05015348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fish oil with omega-3 PUFA
Description: 3.6g per day fish oil with omega-3 PUFA (EPA+DHA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: palm oil as placebo
Study: NCT05662072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Action observation of respiratory exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intervention
Description: Placebo observation
Study: NCT04603066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg with Tariquidar
Description: In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 16 mg with Placebo
Description: In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
Study: NCT06310733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGG
Description: Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
Study: NCT05994872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse drilling technique
Description: A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional extraction drilling
Description: A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel.
Study: NCT05399082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoprobe biopsy
Description: A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forceps biopsy
Description: Biopsy forceps used to collect tissue
Study: NCT04860648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: doctors treat the patients combining the Lus results and clinical practice
Study: NCT05162924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Manual therapy technique applied by a chiropractor in the form of a high-velocity low-amplitude force to the lumbopelvic spine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo spinal manipulation consisting in the application by a chiropractor of a lower-velocity lower-amplitude force to gluteal muscles in a non-intentional direction
Study: NCT06291168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Manipulation (HVLA - High Velocity Low Amplitude)
Description: Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.~After determining that the movement disorder of the sacroiliac joints of the participant is caused by the impaired movement of the ilium in the posterior and inferior direction or the impaired movement of the ilium in the anterior and superior direction, the participant will be asked to take a side lying position.HVLA spinal manipulation was performed for less than one second from posterior to anterior, inferior to superior and medial to lateral directions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-Based Exercise Program
Description: Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification. Patients will be evaluated before treatment, two weeks later, after treatment (at the end of the 8th week) and at the end of the 12th week after treatment (control).~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day.~It will be applied as a yoga session program including breathing and warm-up exercises, suyanamaskar, various relaxation techniques and asanas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week with a physiotherapist. In order to facilitate the memorization and follow-up of the exercises, short videos will be made to facilitate compliance with the exercises by showing the exercises and methods of prevention of low back pain. Individuals will be called to the hospital two days a week for 8 weeks.
Study: NCT04598828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
Study: NCT06197178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-G08 cells
Description: Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.